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Vascularized composite allotransplantation (VCA) offers unparalleled restoration of function and form following
devastating musculoskeletal and soft tissue injury. However, the potential adverse effects of life-long
immunosuppression remain a significant cause for concern. Therefore, while the surgical techniques necessary for VCA
have developed rapidly, the immunological aspects of these procedures and the potential functional significance of
immunological processes on vascularized composite allografts remain areas in which further research is required. The
functional complexity of these procedures, combined with the preclinical nature of many of the research questions,
necessitates the use of large animal models to most effectively address some of the outstanding hypotheses.
Cynomolgus macaques are among the premier large animal models for immunological research. This manuscript
describes development of an orthotopic model of upper extremity transplantation in cynomolgus macaques. Following
study of the anatomy to determine feasibility, in vivo proof of concept was achieved by autologous amputation and
replantation in two animals, following which a preliminary series of four allotransplants was performed. The anatomy
encountered and techniques required for successful transplantation are closely comparable to those in clinical upper
extremity transplantation. This is a technically challenging model, but offers a rigorous pre-clinical platform for
translational research in transplant immunology, and is suitable for detailed study of the impact of immunologic
processes on functional outcomes following VCA.
Introduction
Vascularized composite allotransplantation (VCA) is
established as a treatment option in the management of
complex musculoskeletal and soft tissue trauma and tissue
loss. The utility of these procedures is particularly well
illustrated by transplantation of specialized anatomical
parts such as the upper extremity or those of the craniofa-
cial region, where satisfactory replacement of like with
like, consistent with Gillies’ dictum,1 using autologous
tissue is extremely challenging and results often remain
suboptimal.
Surgical development in VCA has been rapid, based on
decades of experience in autologous free tissue transfer and
microsurgery, and short to medium term results have been
encouraging. Functional outcomes have been remarkable,
particularly in the context of innervation, with hand trans-
plant recipients appearing to benefit from a positive effect
of calcineurin inhibition on peripheral nerve regeneration.2
Recipients of both upper extremity and face transplants
have reported significant improvements in independence
and quality of life post-transplant. Graft survival rates follow-
ing VCA have been largely encouraging, particularly for
upper extremity transplants.3 However this is offset by a
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high incidence of acute rejection episodes (up to 90% expe-
rience at least one episode within the first year) which most
frequently target the skin,3,4 and ongoing concerns regard-
ing the side effect profile of conventional immunosuppres-
sion regimens. In this context, the necessity for further
research into the immunologic responses to vascularized
composite allografts, and development of novel clinical pro-
tocols with reduced risk, improved efficacy, or both is clear.
Murine models have been used extensively to gain
important insights into the basic mechanisms of immune
system function and the establishment and maintenance of
immune tolerance.5 More recently, advances in microsurgi-
cal techniques have facilitated the introduction of murine
VCA models, allowing specific study of skin and musculo-
skeletal tissues in the context of vascularized composites.6
However, historically, the vast majority of protocols which
successfully achieve tolerance of a transplanted organ or tis-
sue in small animal models fail to translate to large animals
or to humans.7 In contrast, mixed chimerism-based toler-
ance protocols originating from murine studies, and vali-
dated in non-human primate models,8 have been
successfully introduced to clinical trials in kidney transplan-
tation.9,10 Therefore, in addition to small animal studies, and
porcine VCA models which we utilize extensively as a cost-
effective large animal model uniquely well suited to the
study of cutaneous immunobiology, we believe that rigor-
ous non-human primate models are an important part of
the translational research pathway in VCA.
Previous studies, performed prior to the introduction of
clinical upper extremity transplantation, sought to investigate
the technical feasibility of hand transplantation in baboons,11
and of partial hand transplants (composites of the first ray
and radial forearm flap) in rhesus macaques.12 More recently,
the radial forearm flap has been described as a model for
study of VCA in cynomolgus macaques,13 although this
model lacked any functional component. Similarly, Barth and
colleagues have described a model of heterotopic transplan-
tation of partial facial allografts14 which they have utilized in
a number of studies of novel immunosuppressive regimens
and the role of donor bone marrow in this context.15,16
This manuscript describes the methodology used for
orthotopic upper extremity transplantation in cynomolgus
macaques and presents results from our preliminary experi-
ence with this model, which permits detailed study of the
immune status of recipients using the wide variety of vali-
dated immunologic techniques and reagents available for
this species, including many cross-reactive human reagents.
In addition the orthotopic transplantation of an upper
extremity, with careful coaptation of nerves and tendons in
a manner comparable to hand transplants in the clinical set-
ting, offers the possibility of functional studies, including
analysis of peripheral nerve testing and functional neuroim-
aging studies, which would not be possible in other model
systems. However, it should be noted that this model
presents a substantial technical challenge, requiring both
surgical precision and careful postoperative management,
which may be further complicated by the characteristics of
the species utilized and which may limit its application in
certain experimental settings.
Methods
All animal procedures described and demonstrated in
this publication were conducted in accordance with proto-
cols approved by the Massachusetts General Hospital Insti-
tutional Animal Care and Use Committee (IACUC), in
accordance with the Guide for the Care and Use of Labora-
tory Animals and under strict veterinary supervision.
1. Preoperative Planning and Preparation
1.1 Use cynomolgus macaques, purchased from
approved vendors, with body weight greater than
6 kg. Animals should undergo thorough veterinary
evaluation and quarantine prior to surgery. Select
donor-recipient pairs on basis of size match, ABO
blood group, and additional parameters as necessary
for the experiment planned, including major histo-
compatibility complex (MHC) genotyping and expres-
sion of donor-specific markers for chimerism analysis.
1.2 In order to minimize ischemic time, procurement of
the donor limb and recipient amputation should
proceed in parallel. Plan surgery to ensure coordina-
tion of the surgical and anesthetic teams.
1.3 Confirm donor and recipient weights with anes-
thetic team 24 hours prior to transplant, and finalize
orders for any non-anesthetic medications, such as
induction immunosuppression, to be administered
intraoperatively as required by the experimental
protocol.
1.4 Check operating room equipment (critical equip-
ment such as operating microscope and pneumatic
tourniquet should be tested frequently and undergo
routine preventative maintenance) and set up to
facilitate work flow.
1.5 Ensure instruments are available and sterilized (auto-
claved or gas sterilized) including reciprocating saw,
drill, titanium plating set, microsurgical set, microvas-
cular clamps and general dissecting instruments.
In addition to donor and recipient operating tables
with arm tables, back tables will be required for each
animal, and for the sterile orthopedic equipment.
1.6 Withhold solid food for at least 12 hours prior to
surgery for both donor and recipient. Water should
be allowed ad libitum at all times.
2. Induction of Anesthesia and Intraoperative
Monitoring
2.1 On the day of surgery administer premedication
(Glycopyrolate 0.01 mg/kg) and sedative (Ketamine
20mg/kg) drugs IM.
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2.2 Confirm adequate sedation by observation, remove
animals from the cage and transfer to the OR.
Remove hair from the surgical site (left arm) and
additional sites for vascular access (contralateral
arm, lower legs, tail) using clippers.
2.3 Place an appropriately size cuffed endotracheal
tube and connect to anesthesia and ventilator cir-
cuit. Maintain anesthesia with isoflurane 0.5-3%
and, for recipient animals, a continuous infusion of
Ketamine 1mg/ml at a rate of 5-10 ml/hr.
2.4 Position animals on operating table with left arm
extended on arm table, and pneumatic tourniquet
in place. Place Bear Hugger forced air warmer to
maintain body temperature under anesthesia. Lubri-
cate eyes with veterinary eye ointment to prevent
dryness under anesthesia.
2.5 Establish peripheral IV access in short saphenous
veins and/or contralateral basilic veins. Administer
maintenance fluids (0.9% normal saline, 10 ml/kg/
hr) and medications intraoperatively.
2.6 Place a percutaneous arterial line in the ventral
artery of the tail of recipient animals for continual
invasive blood pressure monitoring.
2.7 Insert a self-retaining Foley urinary catheter (5 Fr)
and connect to urometer to facilitate strict monitor-
ing of fluid balance.
2.8 Establish monitoring of pulse, blood pressure, respi-
ratory rate, pulse oximetry, capnography, EKG and
temperature. In addition assess depth of anesthesia
by assessment of jaw tone. Monitor and record
these parameters throughout the period of
anesthesia.
2.9 Administer preoperative analgesics (Buprenorphine
0.01 mg/kg IV, Banamine 1 mg/kg IM) and prophy-
lactic antibiotics (Cefazolin 25 mg/kg IM).
2.10 Perform disinfectant skin preparation with solutions
of chlorhexidine, povidone-iodine and alcohol and
drape the surgical field.
3. Recipient Preparation
Induction immunosuppression may be administered
intravenously to the recipient during the transplant proce-
dure, however the details of immunosuppressive protocols
are expected to be the focus of experimental studies using
this model, and to therefore varying considerably. For this
reason we have not included specific steps describing the
administration of immunosuppressive reagents in this
protocol.
3.1 Mark course of cephalic vein and other substantial
cutaneous veins with surgical ink. Design and mark
skin flaps to interdigitate with donor skin flaps
approximately 4cm proximal to radiocarpal joint.
3.2 Elevate and compress arm to exsanguinate, inflate
tourniquet to 200 mmHg.
3.3 Incise skin and elevate skin flaps, taking care to pre-
serve cephalic and other cutaneous veins. Ensure
hemostasis with bipolar diathermy.
3.4 Open investing fascia and dissect out radial
artery and venae commitantes (VCs). Note that
the radial artery may be bifid at this level in cyno-
molgus macaques with each branch accompanied
by VCs.
3.5 Protecting cephalic vein and radial vascular bundle,
divide the superficial digital flexors. Note that the
musculotendinous junction extends further distally
in comparison to human anatomy and division of
muscle is likely at this level.
3.6 Identify, isolate and divide the median nerve. Sec-
tion as far distal as possible and mark for later
identification.
3.7 Isolate and protect the ulnar nerve and ulnar artery
deep to flexor carpi ulnaris, which should be
divided. Ligate the ulnar artery with clips and divide;
this should be handled carefully as it may be
required for secondary arterial anastomosis later.
Divide ulnar nerve distally and mark for
identification.
3.8 Divide the flexor digitorum profundi and the wrist
flexors.
3.9 Divide the digital and wrist extensors.
3.10 Divide pronator quadratus and perform minimal
periosteal stripping to prepare the osteotomy sites,
which should be measured at 4cm from the radio-
carpal joint.
3.11 Ligate and divide radial artery and cephalic vein.
Amputate hand with reciprocating saw, taking care
to perform well aligned, transverse osteotomies of
radius and ulna.
3.12 Deflate tourniquet, ensure hemostasis with
bipolar diathermy, ligature-clips and bone wax as
necessary. Wrap stump in saline-soaked gauze and
monitor recipient condition while awaiting donor
hand.
4. Donor Operation – Allograft Procurement
Procurement of the donor hand proceeds in a similar
manner to recipient amputation, with the exception that
neurovascular structures sectioned distally in the recipient
should be dissected proximally in the donor prior to division,
to ensure sufficient length is available for tension-free
anastomoses.
4.1 Mark course of cephalic vein and other substantial
cutaneous veins with surgical ink. Design and mark
skin flaps to interdigitate with donor skin flaps
approximately 4cm proximal to radiocarpal joint
(Fig. 1 A).
4.2 Elevate and compress arm to exsanguinate, and
inflate tourniquet to 200 mmHg.
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4.3 Incise skin and elevate skin flaps, taking care to pre-
serve cephalic and other cutaneous veins. Ensure
hemostasis with bipolar diathermy.
4.4 Open investing fascia and dissect out radial artery
and venae commitantes (Fig. 1 B).
4.5 Protecting cephalic vein and radial vascular bundle,
divide the superficial digital flexors.
4.6 Identify, isolate and dissection out the median
nerve, dividing it 1-2cm proximal to the level of the
skin incision.
4.7 Divide flexor carpi ulnaris, taking care to protect
ulnar nerve and artery lying along its deep margin.
Divide ulnar artery and nerve proximally, and mark
for identification.
4.8 Divide the flexor digitorum profundi and the wrist
flexors.
4.9 Divide the digital and wrist extensors.
4.10 Divide pronator quadratus and perform minimal
periosteal stripping to prepare the osteotomy sites,
which should be measured at 4cm from the radio-
carpal joint.
4.11 Deflate tourniquet, allowing hand to reperfuse
via radial artery and cephalic vein (Fig. 2 A).
Ensure hemostasis. Administer heparin 200 U/kg
intravenously.
4.12 Allow hand to perfuse for 20-30 minutes, during
which time a tray of sterile ice should be crushed
and heparin-saline (100 U/ml) and perfusion solu-
tion prepared.
4.13 Ligate and divide radial artery and cephalic vein.
The start of ischemic time should be noted.
4.14 Perform radial and ulnar osteotomieswith reciprocating
saw and remove hand to back table on ice (Fig. 2 B)
4.15 Humanely euthanize the donor
animal and collect additional
tissues as necessitated by your
experimental plan.
Note 1: Two options are available for
humane euthanasia; an intravenous
overdose (200mg/kg) of sodium pento-
barbital (Fatal Plus) administered under
sedation, or exsanguination under
deep anesthesia. Use the later only in
experimental circumstances where vital
bone marrow or other tissues to which
sodium pentobarbital may be toxic
must be collected.
Note 2: We routinely collect whole
blood volume for isolation of leuko-
cytes for in vitro assays and prepara-
tion of packed red cells for transfusion
support of anemic animals, bone mar-
row for transplantation and induction
of mixed chimerism, and split thick-
ness skin grafts for later testing of
tolerance.
Figure 1. Marking and dissection for procurement of NHP donor hand.
(A) Skin flaps are marked approximately 4cm from wrist on both recipi-
ent and donor to ensure skin flaps interdigitate properly following trans-
plantation. Note that the course of the cephalic vein is also marked. (B)
Dissecting proximally along the radial vascular bundle to procure addi-
tional length facilitates tension-free anastomosis.
Figure 2. Isolation and amputation of the donor hand. (A) Following dissection and transection of
all major structures except the radius, ulna, radial artery and cephalic vein the tourniquet is
released, the donor heparinized and the hand reperfused for 20–30 minutes prior to procurement.
(B) Following ligation and division of the radial artery and cephalic vein osteotomies are performed
with a reciprocating saw.
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5. Transplantation
5.1 With the hand on ice, cannulate
the radial artery using an ante-
rior chamber needle and 10ml
syringe and flush with heparin-
saline 100U/ml followed by per-
fusion solution (University of
Wisconsin, or Euro-Collins) until
venous effluent is clear.
5.2 Transfer hand to recipient table
and ensure donor and recipient
osteotomies are parallel and will
permit well aligned rigid fixation.
5.3 Perform osteosynthesis with
appropriately sized, titanium lim-
ited contact dynamic compres-
sion plates (LCDCP) and titanium
screws. Use 2.0 mm plates for
animals between 6 – 10kg. Fix
ulna first with a 4-hole plate, fol-
lowed by radius with a 6-hole
plate, 8mm and 10mm screws
respectively are appropriate in
the majority of cases. Follow AO
principles and ensure rigid fixa-
tion to minimize risk of non-
union (Fig. 3).
5.4 Repair wrist flexors and exten-
sors to stabilize wrist in a neutral
position using 3/0 prolene or
ethibond suture.
5.5 Repair deep digital flexor ten-
dons to mimic natural digital
cascade using 3/0 prolene or
ethibond suture.
5.6 Bring in operating microscope
and perform microvascular anas-
tomoses of radial artery followed
by cephalic vein. The artery can
be expected to have a diameter
of <1 mm and the vein 1-1.5
mm, 10/0 nylon suture is appro-
priate (Fig. 4).
5.7 Remove microvascular clamps and allow hand to
reperfuse. Note end of ischemic time. Apply lidocaine
1% to vessels to relieve vasospasm, ensure recipient
is well hydrated with adequate blood pressure and
body temperature, and apply warm saline soaked
gauze wraps to the hand. Allow hand to reperfuse for
20-30 minutes during which time the surgical team
may rotate or take a short rest.
5.8 Assess perfusion. If adequate (hand warm, bright red
bleeding from fingertip following needle prick) pro-
ceed with subsequent steps. If inadequate examine
anastomoses under microscope for patency, ensure
vessel lengths are appropriate to exclude both excess
tension and kinking, and if necessary perform addi-
tional anastomoses to enhance perfusion. A second-
ary branch of the radial artery, or the ulnar artery are
available, additional dorsal veins may be identified.
The venae commitantes of the arteries are of insuffi-
cient caliber for reliable anastomosis.
5.9 Perform median and ulnar neurrorhaphies, aiming to
do so as far distal as possible, using 8/0 or 9/0 nylon
suture.
Figure 3. NHP hand transplantation: Osteosynthesis. (A) Osteosynthesis of ulna and radius is per-
formed using titanium LC-DCPs according to AO principles. Note microvascular clamps on proxi-
mal vessels in preparation for anastomosis. (B) AP and (C) Lateral radiographs demonstrating close
approximation and good alignment of radius and ulna post-transplant.
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5.10 Repair superficial digital flexor tendons with 3/0 pro-
lene or ethibond using low-profile side-to-side
technique.17
5.11 Perform extensor tenorrhaphies using 3/0 prolene
or ethibond, setting tension to allow full range of
motion and maintaining digital cascade.
5.12 Interdigitate and close skin flaps using 3/0 nylon
simple interrupted sutures, taking care to avoid
damage to the cephalic vein or arterial anastomoses
(Fig. 5 A, B)
5.13 Check perfusion adequate (Fig. 5 C) before applying
dressings and cast and recovering the animal to its
cage.
Note that this protocol may be adapted to perform
amputation and autologous replantation if required to
address specific experimental aims, by following the proce-
dures for donor procurement and transplantation on a sin-
gle animal. Shortening osteotomies of 5-10mm to radius
and ulna may be necessary to relieve tension on neurovas-
cular structures and facilitate anastomoses.
6. Postoperative Care
6.1 Dress hand and wound with gauze and bulky wool,
and apply a full-length fiberglass cast to the arm
with the wrist slightly extended, and the metacarpo-
phalangeal and interphalangeal joints loosely flexed
in a natural cascade position.
Note: The elbow should be slightly flexed to prevent
effortless removal of the cast, while simultaneously avoiding
vascular constriction at the antecubital fossa.
6.2 Place animal in a cotton jacket. Secure cast to front
of jacket to achieve relief from dependent position.
Note: Animals must be acclimated to wearing of jackets
and casts prior to commencing study.
6.3 Ensure adequate hydration and analgesia. If placed
in protective jacket, a fentanyl patch 1–4 mg/kg/hr
may be placed to provide postoperative analgesia.
Alternatively buprenorphine 0.01 mg/kg IM must be
administered twice daily for 72 hours, more fre-
quently if clinical signs of pain are observed.
6.4 Wean from anesthesia, discontinue monitoring.
6.5 Return to cage, which should be warmed with a
heat lamp, and monitor continually until fully alert
and recovered from anesthesia.
6.6 Perform examination of the transplanted hand daily
or twice daily for the first 72 hours postoperatively
to ensure adequate perfusion and facilitate rapid
intervention if necessary to revise anastomoses etc.
Short duration sedation for these procedures may
be induced with intramuscular injection of ketamine
(1-4 mg/kg) and dexmedetomidine (5-10 mg/kg),
followed by atipamezole reversal. The frequency of
checks can be reduced to twice weekly after the
immediate postoperative period.
Figure 4. NHP hand transplantation: Reperfusion. Following anastomo-
ses of radial artery and cephalic vein, visible above plates in this photo-
graph, the hand is reperfused for 20–30 minutes and perfusion assessed
prior to continuing with repair of flexor and extensor tendons, median
and ulnar nerves and closure of skin flaps.
Figure 5. Post-transplant appearance: (A) Radial-oblique and (B) ulnar-
oblique views immediately following closure of skin flaps. (C) Bright red
bleeding from fingertip following needle-prick confirms the hand is well
perfused prior to application of dressings and protective cast.
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6.7 Perform 2-view radiographs on post-operative day 1
to ensure fixation is appropriate and the position
acceptable.
6.8 Administer immunosuppressive medications
according to individual experimental protocols.,
Most conventional immunosuppressive agents may
be administered daily via a combination of IM and
oral routes. Draw blood twice weekly to monitor
drug levels. In this study, in the allotransplant group,
immunosuppression was induced with 3 consecu-
tive daily doses of equine anti-thymocyte globulin
(ATGAM) 50 mg/kg IV, and maintained with FK506
0.1 mg/kg/day IM (target trough 15-20 ng/ml), MMF
300 mg/day and methylprednisolone tapered over
the first 2 weeks from 40 mg/day to a maintenance
dose of 1 mg/day.
Experimental Design
The aim of this study was to develop a model of ortho-
topic upper extremity transplantation in cynomolgus
macaques. The first step in this process was to perform post-
mortem dissections to confirm the anatomy of the cynomol-
gus monkey forearm and to determine the feasibility of
transplantation and revascularization (2 animals, group I). We
then performed autologous replantation in 2 animals for in
vivo proof of technical feasibility (group II). Finally, a prelimi-
nary study of 4 allotransplants across full MHC barriers was
performed (group III). The experimental design and details of
the animals in each group are summarized in Table 1.
Representative Results
Post-mortem dissections (in animals euthanized at the
conclusion of their experimental course on other protocols)
confirmed the anatomy of the cynomolgus monkey forearm
was closely conserved with that of humans. A few excep-
tions were noted, chiefly that in both animals examined, the
arterial supply to the hand was provided by 2 arteries in
the radial compartment of the wrist, the medial of which
arose from the radial artery in the distal third of the forearm.
The ulnar system appeared to be vestigial, appearing as a
vasonervorum to the ulnar nerve. The radius had a mean
diameter of 10 mm and the ulna 5mm, suitable for osteosyn-
thesis with 2 mm plates and screws.
Satisfied with the feasibility of transplantation and revas-
cularization, we proceeded to perform a series of 2 autolo-
gous replants and 4 allotransplants across full MHC barriers.
Total operating time averaged 11–12 hours. Mean ischemic
time in both in vivo groups was 3 hours. All microvascular
anastomoses were performed using conventional suture
techniques for both artery and vein, which had diameters of
0.75–1 mm and 1–1.5 mm respectively. All anastomoses
were demonstrably patent with no primary failures.
In the autologous replantation group (group II), one ani-
mal unfortunately developed respiratory complications
under anesthesia, secondary to endotracheal tube trauma,
from which resuscitation could not be achieved. The second
animal in this group tolerated the procedure well, made
impressive functional recovery, including use of the hand in
locomotion, grooming and as an assist hand while feeding
and manipulating objects. This animal remains under follow
up over 2 y post-operatively.
Outcomes following allotransplantation (group III) have
highlighted the critical importance of precise microsurgical
technique, and the challenges of microvascular procedures on
this small scale in animal models. Two animals unfortunately
required early euthanasia due to microvascular compromise;
in one case excess length following venous anastomosis per-
mitted the development of kinking and venous thrombosis on
POD2. Despite emergency revision, a no-reflow state had
developed and the hand could not be reperfused. In another
case, despite patent anastomoses, and treatment with topical
lidocaine 1% for relief of vasospasm, perfusion of the hand
was poor postoperatively and despite medical optimization,
warming, and anticoagulation perfusion remained poor. Per-
sisting ischemia declared over the first postoperative week
and the animal was euthanized on POD7.
The remaining 2 animals in the initial allotransplant group
had smooth operative courses, and made excellent post-
operative recoveries. The first was followed to an experimen-
tal end point 4 months post-transplant, during which period
immunosuppression was maintained with FK506 0.1 mg/kg/
day, MMF 300 mg/day andmethylprednisolone tapered from
over the first 2 weeks from 40 mg/day to a maintenance
dose of 1 mg/day, following ATGAM induction. This regimen
Table 1. Experimental design and animal data
Group Animal ID Number Sex Weight (kg) Recipient Blood Group Donor Blood Group MHC Mismatch
I PM Tissue #1 M 9.0 N/A N/A N/A
PM Tissue #2 M 8.5 N/A N/A N/A
II M5612 M 6.8 AB N/A Auto (replant)
M5712 M 8.2 AB N/A Auto (replant)
III M1413 M 6.5 A A Full
M5812 M 7.5 AB AB MHCI single haplotype shared
M4313 M 8.5 B B Full
M4213 M 9.2 B B Full
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resulted in rejection-free survival (Fig. 6A–C), with the excep-
tion of 1 episode of acute rejection of skin which followed
tapering of MMF to 100 mg/day due to a period of inappe-
tence. Signs of rejection resolved rapidly in response to ste-
roid bolus and return to standard MMF dosing. The final
animal in this group experienced a smooth interoperative
course, and the hand reperfused rapidly on completion of
vascular anastomoses. A surgical site infection was diagnosed
during the second post-operative week following observa-
tion of a suture line abscess and local erythema of adjacent
transplanted and recipient skin. This resolved promptly with
antibiotic therapy, and the hand remained well perfused
with no signs of inflammation until POD 30, whenmild gener-
alized erythema of the donor skin was noted (Fig. 6D, E). A
biopsy was taken and rescue therapy commenced with a cor-
ticosteroid pulse. The biopsy confirmed Banff I acute rejec-
tion (Fig. 6E). Despite continued high-dose corticosteroid
treatment, rejection was progressive
resulting in graft loss and humane
euthanasia on POD51.
Discussion
Non-human primate models are
widely considered the final step on
the translational research pathway
prior to clinical trial. Positive results in
such models are viewed with particu-
lar importance in fields, such as VCA,
where results of current therapies are
acceptable, albeit not always optimal,
and where patient survival is expected
to be high without intervention – thus
establishing that the ethical standard
for any new therapy should be benefi-
cence rather than non-maleficence.
Previously described non-human pri-
mate models of VCA have achieved
transplantation of the necessary tissue
types, and have provided insights into
the immune response to these tissues
under conventional immunosuppres-
sion,13,14 and some novel protocols.15
However, thesemodels include no func-
tional component by which to assess
this important aspect of VCA. This ortho-
topic upper extremity transplantation
model, in contrast, is closely analogous
to clinical hand transplant procedures,
and provides a unique opportunity to
study not only the immune response to
the transplanted tissues, but to investi-
gate in detail the impact of rejection, or
aspects of novel tolerance or immuno-
modulatory protocols on functional out-
come. Representative results from such studies are not yet
available, but investigation of peripheral nerve recovery, func-
tional testing, and advanced imaging studies are planned.
This model is technically challenging, and presents a steep
learning curve as illustrated by the results presented. High qual-
ity, rigid boney fixation is critical in avoiding non-union. Precise
microvascular technique is also imperative, as we have found
this model highly sensitive to even minor excess vessel length,
particularly following venous anastomosis. Typically we observe
satisfactory perfusion of the transplanted hand following anas-
tomosis of radial artery and cephalic vein alone. In two cases we
have performed secondary arterial anastomoses using
branches of the radial artery, which interestingly, appears bifid
in these animals. Venous drainage via the cephalic vein has gen-
erally been sufficient, with the notable exception of the case in
which kinking and occlusion of the vein resulted in thrombosis,
congestion and no-reflow phenomenon, however anastomosis
Figure 6. Representative result: (A) Radial and (B) Palmar views demonstrating status 3 months post
hand transplantation (M1413). Note sutures following protocol biopsy, which confirmed rejection-
free status. (C) Hand transplant biopsy specimen demonstrating absence of rejection. Immunosup-
pression was maintained with FK506 0.1 mg/kg/day, MMF 300 mg/day and Methylprednisolone
1 mg/day. (D) Radial and (E) Palmar views demonstrating appearance of hand during acute rejection
(M4213, POD30) (F) Corresponding histology demonstrating Banff grade I acute cellular rejection.
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of one or more radial artery venae comitantes may provide a
greater margin of safety in animals which do not tolerate eleva-
tion of the arm during the immediate postoperative period.
With regard to immunosuppression, in this preliminary
study we have utilized a protocol of ATGAM induction fol-
lowed by maintenance with tacrolimus, mycophenolate
mofetil and methylprednisolone, adopted from experimen-
tal solid organ transplant protocols in macaques at our insti-
tution. This appears sufficient to prevent graft loss to
rejection post-transplant, albeit requiring doses higher than
typical in clinical use. The observation of progressive, ste-
roid-refractory rejection in one animal is consistent with sim-
ilar findings in solid organ transplantation models (Madsen J,
unpublished data). Taken together these observations dem-
onstrate that the cynomolgus macaque represents a robust
preclinical model for transplantation research. Further stud-
ies are underway utilizing this model for investigation of
clinically applicable tolerance strategies.
This model is resource intensive, requiring an appropriate
non-human primate research facility, expert veterinary anes-
thetic support and a team of experienced reconstructive
microsurgeons. Clearly structured rehabilitation to maximize
functional outcomes is not possible in NHPs as it is in
patients, and this could represent a limitation of this model
when it comes to future functional studies. However we
have been impressed by the considerable degree of func-
tion which animals recover spontaneously, including use of
the hand in grooming, as an assist hand in feeding, and for
locomotion. We believe this model represents a valuable
tool in the effort to validate novel protocols to improve the
immunologic management of VCA, and we hope, ultimately
to facilitate the introduction of a safe and effective protocol
for induction of VCA tolerance to clinical trial. However, the
inherent technical and logistical challenges, not to mention
the ethical obligations associated with research in nonhu-
man primates may limit application of this model to
late-stage proof of concept studies immediately preceding
translation to clinical trial.
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